The Eph receptor tyrosine kinase (RTK) family is the largest subfamily of RTKs playing 29 critical roles in many developmental processes such as tissue patterning, neurogenesis 30 and neuronal circuit formation, angiogenesis, etc. How the 14 Eph proteins, via their 31 highly similar cytoplasmic domains, can transmit diverse and sometimes opposite 32 cellular signals upon engaging ephrins is a major unresolved question. Here we 33 systematically investigated the bindings of each SAM domain of Eph receptors to the 34 SAM domains from SHIP2 and Odin, and uncover a highly specific SAM-SAM 35 interaction-mediated cytoplasmic Eph-effector binding pattern. Comparative X-ray 36 crystallographic studies of several SAM-SAM heterodimer complexes, together with 37 biochemical and cell biology experiments, not only revealed the exquisite specificity 38 code governing Eph/effector interactions but also allowed us to identify SAMD5 as a 39 new Eph binding partner. Finally, these Eph/effector SAM heterodimer structures can 40 explain numerous Eph SAM mutations identified in patients suffering from cancers and 41 other diseases. 42 43 Keywords ： Eph receptor, ephrin-Eph signaling, SHIP2, Odin, SAM domain, 44 SAMD5 45 Lee et al., 2012; Leone et al., 2009; Mercurio et al., 2012; Zhuang et al., 2007), though 87 the binding properties of the SAM domains from other Eph receptors are largely 88 unknown. Second, although the PBM sequences of Eph receptors are somewhat 89 5 different, the short PBM-mediated target bindings are rather promiscuous (Ye and 90 Zhang, 2013) and thus unlikely to be fully responsible for the very diverse Eph 91 intracellular signaling events. In this study, we systematically characterized and 92 compared the bindings of the SAM domain from every Eph receptor to the SAM 93 domains from SHIP2 and Odin. This characterization revealed a highly specific Eph 94 SAM and effector SAM binding pattern. We then elucidated the mechanistic basis 95 governing such specific Eph SAM and effector SAM binding by solving several pairs 96 of the SAM-SAM heterodimer complexes structures. Such comparative structural 97 analysis, together with biochemical, bioinformatics and cell biology studies, revealed 98 an exquisitely specific effector binding code mediated by the Eph SAM domains, which 99 helps to answer the major question on the ephrin-Eph forward signaling specificity. 100 Additionally, our study also provides mechanistic explanations to numerous disease-101 causing mutations identified in the SAM domains of Eph receptors, and allows us to 102 discover SAMD5 as a new intracellular effector of Eph receptors. 103 104
Introduction
The Eph (Erythropoietin Producing Hepatocyte) transmembrane receptor tyrosine 47 both complexes are sufficiently long and flexible ( Figure S1 ). in both complexes is that the backbone methylene of a Gly residue at the beginning of 159 α5 from Eph SAM (Gly954 A2 /Gly1104 A6 ) is in close contact with an aromatic residue 160 from SHIP2/Odin SAM (Trp1221 SHIP2 /Phe738 Odin ) ( Figure 2B&D and Figure S4 ). As 161 such, replacing Gly at the beginning of α5 of Eph SAM with any other amino acid 162 residues will introduce steric hindrance in preventing their binding to SHIP2/Odin 163 SAM. It is further noted that Gly is highly preferred at the beginning of α5 among Eph 164 SAM domains (12 out of the 14 members are Gly; see Figure S5A ). 165 The very high-resolution crystal structures of the two complexes also allowed us 166 to identify a unique interaction feature that is critical for the exquisite specific 167 interaction between the EphA2/A6 SAM domain and SHIP2/Odin SAM domains. 168 Taking the EphA2/SHIP2 complex as the example, a special cation-π interaction 169 between the Arg958 A2 and Phe1226 SHIP2 was uncovered by the high-resolution crystal 170 structure ( Figure 2F ). The guanidinium group of Arg958 A2 forms hydrogen bond 171 network with Asp1222 SHIP2 and His955 A2 on one side and with the backbone carbonyl 172 oxygen of Ile917 A2 . As such the guanidinium plane of Arg958 A2 (and its delocalized π-173 system) is in the same plane with the π-system of the planer peptide bond between 174 Ile917 A2 and Lys918 A2 , forming energetically favorable π-π stacking with the benzene 175 ring of Phe1226 SHIP2 ( Figure 2F ) (Ma and Dougherty, 1997) . The exactly same 176 interaction pattern occurs for the EphA6/Odin complex ( Figure 2G ). It is predicted that 177 alteration of any of the interactions in the above described π-π stacking will perturb the 178 binding of EphA2/6 to SHIP2 or Odin. The most subtle substitution of Arg is probably 179 by the positively charged Lys. Consistent with the binding pattern, the corresponding 180 residue of Arg958 in EphA2 is also found in EphA1 and A6, which could interact with 181 SHIP2 and Odin. Whereas the rest of Eph SAMs contain a Lys in this position except 182 EphA10, which is an Ala ( Figure S5 ). Based on the structures shown in Figure 2F , 183 replacing Arg958 A2 with Lys would eliminate the planar π-system formed by Arg958 A2 184 and the Ile917 A2 -Lys918 A2 peptide bond and thus seriously weaken the binding, even 185 though the positive charge at the site is retained. Totally consistent with this structural 186 analysis, substitution of Arg958 A2 with Lys completely eliminated the bindings of 187 EphA2 SAM to SHIP2 SAM or Odin SAM ( Figure 2H&I ). Correspondingly, 188 substitution of Phe1226 of SHIP2 SAM with non-aromatic hydrophobic residues (e.g.
189
Leu or Ala) also totally eliminated the binding between SHIP2 SAM and EphA2 SAM 190 ( Figure 2H&J ). Additionally, replacing Asp1222 in SHIP2 SAM with Ala also 191 eliminated the binding between SHIP2 and EphA2, highlighting the importance of the 192 hydrogen bond between Asp1222 SHIP2 and Arg958 A2 in stabilizing the guanidinium 193 group of Arg958 ( Figure 2H ). We mined COSMIC cancer somatic mutation database Figure 2H&I ).
198
The above structural and biochemical analysis highlights the critical role and the 199 exquisite selectivity of Arg958 in EphA2 (or the corresponding Arg in EphA1/EphA6) 200 in terms of bindings to the effectors such as SHIP2 and Odin. We pushed this concept 201 further by testing whether we might be able to convert a non SHIP2/Odin binding Eph 202 SAM domain into a binding one by simply substituting the Lys at the position 203 corresponding Arg958 A2 to Arg (i.e. a single residue "gain-of-function" mutation). We 204 chose EphA5 SAM domain to test this hypothesis, as it shares ~50% sequence identity 205 to EphA2 SAM but has no or minimal binding to SHIP2 or Odin ( Figure 2H ).
206
Satisfyingly, substituting Lys857 (corresponding Arg958 A2 ) with Arg converted EphA5 207 SAM into a SHIP2 binding SAM domain, though the binding was still relatively weak.
208
The same substitution also enhanced EphA5 SAM's binding to Odin SAM1 by more To focus our studies on the forward signal pathway of EphA2, we chose to engage the 220 EphA2 receptor by adding soluble ephrinA1-Fc chimera to the cell culture media. To To delineate the mechanism governing the Eph/SAMD5 interaction, we solved the 262 EphA5/SAMD5 SAM-SAM complex crystal structure at the resolution of 1.9 Å ( Table   263 1). Similar to that of EphA2/SHIP2 or EphA6/Odin, EphA5 SAM also uses its End-
264
Helix to interact with the Mid-Loop SAMD5 SAM ( Figure 5A&B ). However, their 265 detailed binding mechanisms are quite different. The most prominent difference is that 266 the EphA5/SAMD5 SAM-SAM does not contain the π-π stacking observed in the 267 EphA2/SHIP2 and EphA6/Odin complexes ( Figure 5C ). Instead, the EphA5/SAMD5 268 SAM-SAM is essentially completely mediated by charge-charge and hydrogen bonding 269 interactions ( Figure 5C ). Perturbation of these interactions invariably weakened the 270 interaction ( Figure 5E ). Similar to what we observed in the EphA2/SHIP2 and EphA3/EphA4/EphA10/EphB6, each has one or more of the key residues missing (e.g.
283
EphA10 and EphB6 are missing Gly at the beginning of α5, and EphA3/4 SAMs are 284 missing positively charged Lys at the end of α2 or in the middle of α5; Figure S5 ). For 285 the EphA1/EphA2 SAM domains, although all the key residues are present, it is noticed 286 that a Pro residue is at the position corresponding to Val852 A5 ( Figure S5 ). The 287 sidechain pyrrolidine ring of Pro would introduce steric hindrance with Asp40, and thus 288 may perturb SAMD5 from binding to EphA1/EphA2 SAM domains ( Figure 5D ), 289 resulting in low affinities ( Figure 4D ). Supporting this analysis, replacing Val825 of 290 EphA5 SAM with a Pro led to about 10-fold affinity decrease in its binding to SAMD5. 291 Additionally, substitution Pro953 in EphA2 with a smaller residue Ala increased its 292 SAMDs SAM binding by more than 10 fold ( Figure 5E ). Finally, EphA6 SAM could 293 bind to both SAMD5 and SHIP2/Odin SAM domains ( Figure 1D&4D ), since it satisfies 294 the binding criteria of both types. that numerous mutations occur in almost every subtype of Eph genes except for EphB6.
304
A significant number of these mutations fell into the SAM domain regions ( Figure 6A ).
305
The biochemical and structural information provided in this study allowed us to test the 306 impact of these mutations found in cancer patients in terms of binding to the Figure 6A . We purified each of these mutant SAM domains of 311 Eph proteins, and measured their individual bindings to SHIP2 SAM or SAMD5 SAM 312 by ITC-based assays. The results are summarized in Figure 6B and C. As expected, 313 EphA1 R966C, EphA2 R957C, and EphA6 R1014Q mutations (the cation-π forming 314 Arg at α5 helix) totally abolished their binding to SHIP2 ( Figure 6B ). Similar 315 deleterious effect can also be seen in EphA1 α1-α2 loop mutation R926G ( Figure 6B ).
316
EphA5 G1014S, EphA7 G972V, and EphB3 G974D mutations disrupted their binding 317 to SAMD5 ( Figure 6C ), further supporting our structural finding that the sidechain-less 318 Gly at the beginning of α5 is critical ( Figure S4 ). Mutations on other critical sites such 319 as EphA5 K1018M, EphA6 R1014Q, EphA8 R943H, and EphB1 K926M, A961T all 320 weakened or even disrupted their binding to SAMD5 ( Figure 6C ). Taken together, the 
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We demonstrated that, unlike many other previously characterized polymer mutations of residues in the folding core or residues playing other critical structural 373 roles (e.g. residues highlighted in red in Figure 6A ) may impair the overall structure 374 and thus effector binding of Eph SAM domains. We tested a few of such mutations (e.g.
375
EphA2 W913C and D944N), and found that these SAM mutants invariably expressed 376 as inclusion bodies (data not shown). Second, mutations occur in the End-Helix region 377 of Eph SAM domains. This category of Eph SAM domain mutants often has defects or 378 even total impairments in binding to their effectors ( Figure 6B&C ), and thus are 379 expected to have impair downstream signaling. Third, mutations occur in the Mid-Loop 380 region of the Eph SAM domains may also impair their binding to effector SAM domain 381 as we mentioned above, although this prediction will need to be verified. We propose 382 that the Eph SAM mutations found in patients that fall into the above three categories 383 will have higher chance to be disease-relevant mutations and thus are given higher 384 priority to be investigated. Certainly, it cannot be ruled out that mutations of the Eph 385 SAM domains that are outside the three categories may also impair functions of Eph 386 receptors, perhaps via still unknown SAM domain-mediated target bindings. 
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The lenti-viruses were used to infect DU145 cells and selected with 1 μg/mL puromycin 462 for ten days and the expression levels of proteins were verified by immunoblotting.
463
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Fleckenstein, B., and Neipel, F. The backbone methylene of a Gly residue at the beginning of α5 from Eph SAM 747 (Gly954 A2 /Gly1104 A6 ) is in close contact with an aromatic residue from SHIP2/Odin SAM 748 (Trp1221 SHIP2 /Phe738 Odin ) (A&B). In EphA5/SAMD5 complex, Gly853 is in close contact with 749 G27 SAMD5 backbone and V32 SAMD5 sidechain (C). The black dashed lines indicate the distances 750 between two atoms are within 4 Å. 
